Denali Therapeutics to Sell FDA Priority Review Voucher for $195M
SOUTH SAN FRANCISCO, Calif., June 18, 2026 Denali Therapeutics Inc. announced it has entered into a definitive agreement to...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
SOUTH SAN FRANCISCO, Calif., June 18, 2026 Denali Therapeutics Inc. announced it has entered into a definitive agreement to...
SOUTH SAN FRANCISCO, Calif., March 25, 2026 In a landmark regulatory milestone, Denali Therapeutics announced that the U.S. Food...
